8th Annual Scientific Meeting of the Cooperative Trials Group for Neuro-Oncology
Quest River Park CentralBrisbane, AUSTRALIA Visit the Venue to read more
I am pleased to invite you to attend this year's COGNO Annual Scientific Meeting, to be held from Friday 23rd October to Saturday 24th October at The Stamford, in Brisbane, Australia.
We are very fortunate to host international speakers of such high-calibre as Professor Martin van den Bent, Professor Kenneth Aldape and Professor Vinay Puduvalli as well as a range of Australian experts for a topical and robust scientific program covering 2 full days.
Themes this year include:
Grade 2 & 3 glioma, the present and the future
Immunogenetics in practice in Australia and internationally, an interactive panel session
‘Can we see it’: Technological advances in Neurosurgery and imaging
Personalising the treatment of brain metastases
Emerging targets in high grade glioma
Management approaches to recurrent high grade glioma
Unforgettable tumours: part II
COGNO is again offering prizes for the best abstracts and we encourage early submission (abstracts close 31 July). In addition to previous prizes offered we are also pleased to offer a Young Investigators prize aimed at encouraging researchers early in their career. The Welcome Reception/Poster walkaround will be held during an extended lunch break on the Friday. It is an excellent opportunity to view the posters on display and chat to colleagues, our international guests, and our sponsors.
Following from the success of the initial fundraising last year, we are delighted to be able to offer a delegate from a lower income country financial assistance to attend the ASM. We are keen to continue and expand this initiative in the future and encourage attendees to consider making a nominal contribution during the registration process (no amount is too small).
This year we plan on hosting our COGNO dinner on the Friday night and hope to see as many faces as possible- an excellent opportunity to relax with friends and colleagues (old and new), and enjoy great cuisine and the charms of Brisbane by the river.
I look forward to welcoming you to Brisbane in October.
Professor Martin J. van den Bent, MD, PhD
Brain Tumor Center at Erasmus MC Cancer Center, Rotterdam, the Netherlands
After completing his training as a neurologist Martin J. van den Bent joined in 1992 the Neuro-Oncology Unit of Erasmus MC - Daniel den Hoed Cancer Center in Rotterdam, the Netherlands. This neuro-oncology unit is focused on the treatment of primary brain tumors and on neurological complications of cancer and its treatment. In 2002 he became the head of the unit, which was in 2013 integrated into the Brain Tumor Center at Erasmus MC Cancer Center. In 2007 he became professor of Neuro-Oncology at Erasmus University. He has been the principle investigator of a large number of international multicenter phase II and III trials on both high and low grade glial tumors, most of which were conducted through the EORTC Brain Tumor Group. Many of these trials included translational research focusing on the identification of prognostic and predictive molecular parameters of outcome to treatment, and which were key in the establishment of the standard of care of diffuse glioma. After being the EORTC Brain Tumor Group secretary from 1996-2002 he served for 6 years as the chair of this internationally well recognized group. He is currently the chair of the EORTC Clinical Research Division. He has established and co-chaired four editions of the bi-annual EORTC-EANO-ESMO educational course on brain tumors, and was between 2001 and 2003 the chair of the Dutch Neuro-Oncology Working group. He was awarded in 2004 and in 2014 the award for excellence in clinical research by the Society for Neuro-Oncology. Prof van den Bent has published widely both on the treatment of primary brain tumors and on neurological complications of systemic cancers. He has been chairing and lecturing at numerous national and international educational symposia and scientific meetings on neuro-oncology, and he is on the editorial board of several oncology journals. He wrote many chapters in textbooks on neuro-oncology, and is active in the Response Assessment in Neuro-Oncology (RANO) group revising the endpoints and response criteria of trials in neuro-oncology.
Professor Vinay K. Puduvalli, MD
Dr Vinay Puduvalli is a tenured Professor and the Director of the Division of Neuro-Oncology at The Ohio State University Wexner Medical Center and Comprehensive Cancer Center where he holds the Sanford/Rife Chair in Neuro-oncology. Dr. Puduvalli received his medical degree from Bangalore Medical College in Bangalore, India in 1989. He then completed a residency in Neurology at The University of Texas Health Sciences Center in Houston followed by a fellowship in Neuro-Oncology at MD Anderson Cancer Center, Houston before joining the faculty there in 1999. He was the director of neuro-oncology fellowship and director of clinical research practicing in MD Anderson for over 15 years. In January 2013, he was recruited to The Ohio State University as the director of the Division of Neuro-Oncology and as co-leader of the brain tumor research group. He also serves as the Medical Director of the Neurological Malignancies service line in the James Cancer Hospital and of the Brain and Spine Tumor Center. His academic interests are focused on patient oriented research using a combination of laboratory based, translational and clinical studies. He has been the principal investigator of several single and multi-institution clinical trials targeting malignant gliomas including through the North American Brain Tumor Consortium and the Brain Tumor Trials Collaborative and serves on the brain tumor committee of the Alliance Clinical Trials Network. He has served on several grant review committees and on various advisory boards for development of novel drugs. He has a strong commitment to education and has mentored a large number of medical students, fellows and junior faculty. His laboratory efforts are focused on epigenetic characterization of gliomas by determining key promoter level interactions of DNA methylation with the stemness genes that regulate their expression; the overall goal of this effort is to identify epigenetic switches governing stem to differentiated states and identify novel therapeutic targets; His lab is also focused on new drug development and testing by characterizing the role of chromatin modification and the role of HDAC in stemness and drug resistance in glioma cells and glioma stem cells. His research efforts have been continuously funded through peer-reviewed federal and nonfederal grants including for studies in novel drugs against gliomas, studies in apoptosis and differentiation and in epigenetics of gliomas. His research is aimed at providing new insights into mechanisms of drug resistance and to translate these findings into clinical trials against brain tumors.
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Please note your ASM registration does not include accommodation. You will need to organise accommodation directly with the hotel of your choice.
We recommend that you book early to secure your preferred accommodation.
Special rates have been negotiated for delegates at Stamford Plaza Brisbane.
• Superior River View Rooms - $245.00 per night
Instructions for booking rooms at this rate will be available soon.
Special rates have also been negotiated at a number of other hotels near Stamford Plaza Brisbane. Please refer to the map for a snapshot of their locations: map.
Quest River Park Central
Location: 120 Mary Street, Brisbane (270 m / 3 min walk)
One Bedroom Apartment - $189.00 per night
Two Bedroom Apartment - $269.00 per night
Three Bedroom Apartment - $455.00 per night
Members of the neuro-oncology community and related professions are invited to submit abstracts for presentation as part of the COGNO Annual Scientific Meeting. Abstracts for both poster and oral presentations including original work in clinical, translational and allied health research will be considered. Abstracts will be reviewed by a Committee representing COGNO and scored on merit against pre-determined selection criteria.
Abstracts must be submitted via the COGNO ASM Presenters Portal. If you encounter difficulties, please contact the COGNO office.
Abstracts should be 300 words maximum including the section headings. The title, authors' names and professional affiliations are not included in the word count.
Abstracts accepted for poster presentation will be displayed during the Meeting. Specifications will be provided.
If your abstract is chosen for oral presentation, you will be contacted with further details.
Abstracts should comprise the following elements, with each beginning a new paragraph:
Title: The abstract title should be in initial capital/lower case, not all capitals. The abstract title should be concise and describe/refer to the content.
Authors: Authors' names should be supplied in capital/lower case, not all capitals. Institutional affiliations should be indicated at Affiliation No. following the author name.
Affiliation: All affiliations should contain institution, city and country.
Abstract text: The abstract should detail the objectives and results of your research project and be structured to include an introduction indicating the purpose of the study (Aims), a brief description of the study methods (Methods), a summary of the results (Results) and a statement of the conclusions (Conclusions).
References: (optional) References can be included in the abstract text. The style of the references should follow the numbered style. Any references included must be cited within the abstract text.
Images: Please feel free to upload up to 3 supporting images for your abstract. Images must be either .gif, .jpg or .bmp format and no larger than 1MB. All images should be cited in the text of the abstract.
Tables: Tables can be included as an image, and must be cited in the abstract text.
All presenting authors of submitted abstracts will be notified as to whether their abstract has been accepted for presentation in September 2015.
All accepted presenters will be required to cover their own costs in attending the COGNO ASM. The deadline for presenters to register is Friday 25 September 2015.
This year there will be three awards available
Young Investigator Award
Most Outstanding Oral Presentation
Most Outstanding Poster Presentation
NHMRC Clinical Trials Centre
Locked Bag 77
Tel: +61 (0)2 9562 5000
Fax: + 61 (0)2 9562 5094
NHMRC Clinical Trials Centre
Locked Bag 77
Tel: +61 (0)2 9562 5000
Fax: + 61 (0)2 9562 5094